Profusa, Inc.

Contributing Author

Recent Articles by Profusa, Inc.

Sep-24	Profusa Announces Significant Progress Towards Lumee Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October PFSA +47.80% GlobeNewswire
Sep-15	Profusa, Inc. Receives Nasdaq Compliance Determination PFSA -29.34% GlobeNewswire
Aug-31	Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement PFSA GlobeNewswire
Aug-20	Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company PFSA -44.22% GlobeNewswire
Aug-13	Profusa Announces 1-for-4 Reverse Stock Split PFSA GlobeNewswire
Jul-31	Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs PFSA PFSA -9.19% GlobeNewswire
Jul-27	Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company PFSA -28.65% GlobeNewswire
Jul-02	Profusa Announces 1-for-25 Reverse Stock Split PFSA -28.08% GlobeNewswire
Jun-24	Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts PFSA -9.72% GlobeNewswire
Jun-12	Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee Oxygen Platform PFSA -17.66% GlobeNewswire
Jun-10	Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting PFSA -9.69% GlobeNewswire
May-15	Profusa Announces Listing Transfer to The Nasdaq Capital Market PFSA GlobeNewswire
May-08	Profusa Receives Favorable Nasdaq Listing Determination PFSA +5.27% GlobeNewswire
May-05	Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value PFSA -6.64% GlobeNewswire
Apr-06	Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform PFSA +144.06% GlobeNewswire
Feb-27	Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering PFSA -14.75% GlobeNewswire
Feb-19	Profusa Receives Purchase Orders for Lumee Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance PFSA GlobeNewswire
Feb-13	Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies PFSA -33.44% GlobeNewswire
Feb-12	Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies PFSA GlobeNewswire
Feb-05	Profusa Announces 1-for-75 Reverse Stock Split PFSA -36.35% GlobeNewswire
Jan-29	Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 PFSA GlobeNewswire
Jan-16	Profusa Launches Lumee Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue PFSA GlobeNewswire
Jan-08	Profusa Adds Leading Greek Vascular Surgeon to Customer Base PFSA GlobeNewswire
Dec-31	Profusa Bolsters European Commercial Network with New French Distributor, MedSell PFSA -13.96% GlobeNewswire
Dec-30	Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 PFSA +78.33% GlobeNewswire
Dec-15	Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 PFSA -19.87% GlobeNewswire
Dec-11	Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 PFSA GlobeNewswire
Nov-24	Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 PFSA +8.38% GlobeNewswire
Nov-19	Profusa Announces Third Quarter Business and Financial Highlights PFSA -5.95% PFSA -19.59% GlobeNewswire
Oct-30	Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee Oxygen and Glucose Monitoring Launches PFSA -9.85% GlobeNewswire
Oct-28	Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026 PFSA GlobeNewswire
Oct-22	Profusa Expands Sales Footprint with New Distributor for Lumee Oxygen Platform in Europe PFSA -8.11% GlobeNewswire
Oct-15	Profusa Expands Sales Footprint with New Distributor for Lumee Oxygen Platform in Europe PFSA GlobeNewswire
Oct-07	Profusa Invests Additional $1 Million in Digital Treasury Assets PFSA GlobeNewswire
Oct-01	Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base PFSA GlobeNewswire
Sep-11	Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring PFSA +74.04% GlobeNewswire
Sep-04	Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base PFSA -7.94% GlobeNewswire
Sep-02	Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference PFSA -7.83% PFSA -5.00% GlobeNewswire
Aug-27	Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria PFSA GlobeNewswire
Aug-19	Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO PFSA -7.99% GlobeNewswire
Aug-06	Profusa, Inc. Provides Strategy Overview and Business Update for Investors PFSA -7.72% GlobeNewswire
Jul-31	Profusa Secures Lumee Oxygen Platform Distributor in Spain PFSA GlobeNewswire
Jul-30	Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy PFSA -17.80% GlobeNewswire
Jul-21	Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy PFSA -17.32% GlobeNewswire

Profusa, Inc.

Recent Articles by Profusa, Inc.

Upgrade your Finviz experience